Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

The PSMA targeting ligand in Pluvicto™, is chemically attached to a therapeutic radioactive atom called Lutetium-177 (177Lu), which releases an energetic beta particle to precisely deliver cell ...

Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with ...

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...

Older adults and middle-aged adults are more at risk of developing cancer, and dying from the deadly disease in India ...

(Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto� (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients with prostate-specific membrane ...